BEYAZ LAWSUIT SETTLEMENTS UPDATE 2012
DROSPIRENONE (DRSP) BLOOD CLOTS: COMMON INGREDIENT IN BEYAZ
Since 2009, multiple scientific studies have confirmed that DROSPIRENONE (DRSP) containing birth control pills present a higher risk of potentially fatal blood clots to users. Blood clots can prove fatal if undetected or untreated. In the United States, the original DROSPIRENONE (DRSP) birth control pill was the trademarked YASMIN. It was followed by YAZ and the generic equivalents of YASMIN – OCELLA and GIANVI. In 2010, the trademarked BEYAZ and SAFYRAL were introduced in the United States. BEYAZ is YAZ with folate added, and SAFYRAL is YASMIN with folate added, both are marketed as providing a way for women to increase folate levels during their reproductive years and to prevent rare neural tube defects in the event they become pregnant, or seek to conceive after discontinuation of BEYAZ.
As of April 2012, published reports indicate that there were nearly 12,000 pending civil lawsuits over DROSPIRENONE (DRSP)containing birth control pills.
There is no differentiation between YAZ vs. BEYAZ or YASMIN vs. SAFYRAL in these reports. Similarly, the number of lawsuits involving generic equivalents is not differentiated. Regardless, the common ingredient in all FDA approved DROSPIRENONE (DRSP) containing birth control is 3 mg of the protestin – DROSPIRENONE (DRSP). The 3 mg is combined with an estrogen, EE (Ethinyl Estradiol) to inhibit reproduction and prevent pregnancy.
However, the novel progestin has arguably been demonstrated to be 3x more likely to cause blood clots, which can lead to strokes, myocardial infarction, heart attacks, pulmonary emboli, deep vein thrombosis, or other life altering complications. An FDA funded study, released in October 2011, found that DROSPIRENONE (DRSP) containing forms of birth control were 74% more likely to cause blood clots, consistent with independent studies.
After nearly three years of civil litigation, on April 10, 2012, FDA announced that all DROSPIRENONE (DRSP) containing birth control pills would carry a new warning communicating the potential for added risks of blood clots. This effectively confirms legal theories advanced, through the present date that, this generation of birth control did not properly or adequately inform prescribers or patients of hazardous risks. Only days later, published reports emerged confirming that the manufacturer, BAYER, had begun settling related blood clot lawsuits on a case by case basis.
The sponsor of this site is offering case evaluations for any girl or woman, in the territorial United States, that has suffered a blood clot from use of BEYAZ.
FREE CASE EVALUATIONS ARE AVAILABLE THROUGH THE USE OF THE CONTACT FORM BELOW.